Shares in commercial biotech company Allergy Therapeutics (LON:AGY) climbed 7.76% to 26.40p (13:20 BST) after the company announced positive top line results from phase II trials for a treatment for glass allergies. All the dosing regimens were safe and well tolerated, with the product showing a significant improvement over placebo.
CEO Manuel Llobet said that, “This study represents a major milestone in our path forward to a registered grass allergy product in Europe. Additionally, this brings us closer towards marketing authorisation in the estimated $2bn US allergy market, a significant opportunity where our product has the potential to be the first registered subcutaneous immunotherapy for the treatment of grass allergy”.
The Master Investor Show 2020 tickets are now available. Join us at the Business Design Centre on Saturday 28 March 2020.
Book your FREE tickets today using code: MIBLOG